Oleamide is a selective endogenous agonist of rat and human CB 1 cannabinoid receptors

British Journal of Pharmacology

Volumn 141, Issue 2, 2004, Pages 253-262

  Leggett, James D ^a   Aspley, S ^b,d   Beckett, S R G ^a   D'Antona, A M ^c   Kendall, D A ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

11 hydroxy dimethylheptyl 8 tetrahydrocannabinol; Cannabinoid agonist; CB 1; CB 2 receptor; Cis 9,10 octadecanoamide; Endocannabinoid; HU210; Human; Oleamide (ODA); Radioligand binding; Rat; Receptor

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BRAIN RECEPTOR; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MEMBRANE RECEPTOR; OLEAMIDE; PERTUSSIS TOXIN; RIMONABANT; SULFUR 35; TRITIUM;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN MEMBRANE; CIS ISOMER; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMPETITION; DRUG EFFECT; DRUG EFFICACY; DRUG LABELING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TRANS ISOMER;

ANIMALS; CELL LINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; HUMANS; MICE; OLEIC ACIDS; PROTEIN BINDING; RATS; RECEPTOR, CANNABINOID, CB1;

EID: 1342343936     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705607     Document Type: Article

References (53)

1. 1 receptor in constitutive activation of Gs. J. Neurochem., 72, 2032-2038.
2. ALVAREZ, R. & DANIELS, D.V. (1992). A separation method for the assay of adenylylcyclase, intracellular cyclic AMP, and cyclic-AMP phosphodiesterase using tritium-labeled substrates. Anal. Biochem., 203, 76-82.
3. 3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol., 137, 589-596.
4. 35S]GTPγS binding in the rat brain. Br. J. Pharmacol., 128, 192P.
5. BISOGNO, T., SEPE, N., DE PETROCELLIS, L., MECHOULAM, R. & DI MARZO, V. (1997). The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem. Biophys. Res. Commun., 239, 473-479.
6. BOGER, D.L., FECIK, R.A., PATTERSON, J.E., MIYAUCHI, H., PATRICELLI, M.P. & CRAVATT, B.F. (2000a). Fatty acid amide hydrolase substrate specificity. Bioorg. Med. Chem. Lett., 10, 2613-2616.
7. BOGER, D.L., HENRIKSEN, S.J. & CRAVATT, B.F. (1998). Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signalling molecules. Curr. Pharm. Design, 4, 303-314.
8. BOGER, D.L., SATO, H., LERNER, A.E., GUAN, X. & GILULA, N.B. (1999). Arachidonic acid amide inhibitors of gap junction cell-cell communication. Bioorg. Med. Chem. Lett., 9, 1151-1154.
9. BOGER, D.L., SATO, H., LERNER, A.E., HEDRICK, M.P., FECIK, R.A., MIYAUCHI, H., WILKIE, G.D., AUSTIN, B.J., PATRICELLI, M.P. & CRAVATT, B.F. (2000b). Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. U.S.A., 97, 5044-5049.
10. BORING, D.L., BERGLUND, B.A. & HOWLETT, A.C. (1996). Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids, 55, 207-210.
11. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
12. BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155-163.
13. CHEER, J.F., CADOGAN, A.K., MARSDEN, C.A., FONE, K.C.F. & KENDALL, D.A. (1999). Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology, 38, 533-541.
14. CHIN, C.N., MURPHY, J.W., HUFFMAN, J.W. & KENDALL, D.A. (1999). The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, the peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther., 29, 837-844.
15. COYNE, L., LEES, G., NICHOLSON, R.A., ZHENG, J. & NEUFIELD, K.D. (2002). The sleep hormone oleamide modulates inhibitory ionotropic receptors in mammalian CNS in vitro. Br. J. Pharmacol., 135, 1977-1987.
16. CRAVATT, B.F., PROSPERO-GARCIA, O., SIUZDAK, G., GILULA, N.B., HENRIKSEN, S.J., BOGER, D.L. & LERNER, R.A. (1995). Chemical characterization of a family of brain lipids that induce sleep. Science, 268, 1506-1509.
17. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
18. DI MARZO, V. (1998). Endocannabinoids and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta, 1392, 153-175.
19. DI MARZO, V., BREIVOGEL, C.S., TAO, Q., BRIDGEN, D.T., RAZDAN, R.K., ZIMMER, A.M., ZIMMER, A. & MARTIN, B.R. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434-2444.
20. DOUGALIS, A., LEES, G. & GANELLIN, R.C. (2004). The sleep inducing brain lipid cis-oleamide (cOA) does not modulate serotonergic transmission in the CA1 pyramidal neurons of the hippocampus in vitro. Neuropharmacol, 46, 63-73.
21. FEDOROVA, I., HASHIMOTO, A., FECIK, R.A., HEDRICK, M.P., HANUS, L.O., BOGER, D.L., RICE, K.C. & BASILE, A.S. (2001). Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther., 299, 332-342.
22. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., GLASS, M., MACKIE, K.P., FAHEY, K.J., CULLINAN, G.J., HUNDEN, D.C., JOHNSON, D.W., CHANEY, M.O., KOPPEL, G.A. & BROWNSTEIN, M. (1998). LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther., 284, 291-297.
23. FELDER, C.C., JOYCE, K.E., BRILEY, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. & MITCHELL, R.L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443-450.
24. GLASS, M. & FELDER, C.C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 17, 5327-5333.
25. 35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther., 285, 553-560.
26. HEDLUND, P.B., CARSON, M.J., SUTCLIFFE, J.G. & THOMAS, E.A. (1999). Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem. Pharmacol., 58, 1807-1813.
27. HILLARD, C.J., EDGEMOND, W.S. & CAMPBELL, W.B. (1995). Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. J. Neurochem., 64, 677-683.
28. HUIDOBRO-TORO, J.P. & HARRIS, R.A. (1996). Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors. Proc. Natl. Acad. Sci. U.S.A., 93, 8078-8082.
29. HUITRON-RESENDIZ, S., GOMBART, L., CRAVATT, B.F. & HENRIKSEN, S.J. (2001). Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp. Neurol., 172, 235-243.
30. IWAMURA, H., SUZUKI, H., UEDA, Y., KAYA, T. & INABA, T. (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 296, 420-425.
31. LAMBERT, D.M. & DI MARZO, V. (1999). The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem., 6, 757-773.
32. A receptor β3 subunit eliminates the hypnotic actions of oleamide in mice. NeuroReport, 12, 4143-4147.
33. 35S]GTPγS binding in rat brain preparations via a cannabinoid receptor. Br. J. Pharmacol., 137, 114P.
34. LICHTMAN, A.H., HAWKINS, E.G., GRIFFIN, G. & CRAVATT, B.F. (2002). Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther., 302, 73-79.
35. MANG, C.F., ERBELDING, D. & KILBINGER, H. (2001). Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br. J. Pharmacol., 134, 161-167.
36. MECHOULAM, R. & FRIDE, E. (1995). The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. In Cannabinoid Receptors. ed. Pertwee, R.G. pp. 233-258 Academic Press, London.
37. MECHOULAM, R., FRIDE, E., HANUS, L., SHESKIN, T., BISOGNO, T., DI MARZO, V., BAYEWITCH, M. & VOGEL, Z. (1997). Anandamide may mediate sleep induction. Nature, 389, 25-26.
38. MENDELSON, W.B. & BASILE, A.S. (1999). The hypnotic actions of oleamide are blocked by a camabinoid receptor antagonist. NeuroReport, 10, 3237-3239.
39. MURILLO-RODRIGUEZ, E., SANCHEZ-ALAVEZ, M., NAVARRO, L., MARTINEZ-GONZALEZ, D., DRUCKER-COLIN, R. & PROSPERO-GARCIA, O. (1998). Anandamide modulates sleep and memory in rats. Brain Res., 812, 270-274.
40. MURILLO-RODRIGUEZ, E., GIORDANO, M., CABEZA, R., HENRIKSEN, S.J., DIAZ, M.M., NAVARRO, L. & PROSPERO-GARCIA, O. (2001). Oleamide modulates memory in rats. Neurosci. Lett., 313, 61-64.
41. PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129-180.
42. PERTWEE, R.G. & ROSS, R.A. (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids, 66, 101-121.
43. 3H]SR141716A. Neuroreport, 7, 789-792.
44. RALEVIC, V., KENDALL, D.A., BENNETT, T. & GARDINER, S.M. (2000). Comparison of the effects of anandamide and methanandamide in bioassays. Br. J. Pharmacol., 129, 141P.
45. 3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. Life Sci., 58, 1239-1247.
46. SHESKIN, T., HANUS, L., SLAGER, J., VOGEL, Z. & MECHOULAM, R. (1997). Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 40, 659-667.
47. SONG, Z.H. & BONNER, T.I. (1996). A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol., 49, 891-896.
48. SUGIURA, T., KONDO, S., KODAKA, T., TONEGAWA, T., NAKANE, S., YAMASHITA, A., ISHIMA, Y. & WAKU, K. (1996). Enzymatic synthesis of oleamide (cis-9, 10-octadecenoamide), sleep-inducing lipid, by rat brain microsomes. Biochem. Mol. Biol. Int., 40, 931-938.
49. THOMAS, E.A., CARSON, M.J., NEAL, M.J. & SUTCLIFFE, J.G. (1997). Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. U.S.A.. 94, 14115-14119.
50. THOMAS, E.A., CRAVATT, B.F. & SUTCLIFFE, J.G. (1999). The endogenous Iipid oleamide activates serotonin 5-HT7 neurons in mouse thalamus and hypothalamus. J. Neurochem., 72, 2370-2378.
51. WILEY, J.L. & MARTIN, B.R. (2002). Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids, 121, 57-63.
52. YANG, J.Y., WU, C.F. & SONG, H.R. (1999). Studies on the sedative and hypnotic effects of oleamide in mice. Arzneimittelforschung, 49, 663-667.
53. ZHOU, D. & SONG, Z.H. (2001). CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. J. Neurosci. Res., 65, 346-353.